A validation of the Oswestry Spinal Risk Index by Whitehouse, S. et al.
University of Huddersfield Repository
Whitehouse, S., Stephenson, John, Sinclair, V., Gregory, J., Tambe, A., Verma, R., Siddique, Irfan 
and Saeed, Mohammad
A validation of the Oswestry Spinal Risk Index
Original Citation
Whitehouse, S., Stephenson, John, Sinclair, V., Gregory, J., Tambe, A., Verma, R., Siddique, Irfan 
and Saeed, Mohammad (2014) A validation of the Oswestry Spinal Risk Index. European Spine 
Journal. ISSN 0940-6719 
This version is available at http://eprints.hud.ac.uk/22491/
The University Repository is a digital collection of the research output of the
University, available on Open Access. Copyright and Moral Rights for the items
on this site are retained by the individual author and/or other copyright owners.
Users may access full items free of charge; copies of full text items generally
can be reproduced, displayed or performed and given to third parties in any
format or medium for personal research or study, educational or not-for-profit
purposes without prior permission or charge, provided:
• The authors, title and full bibliographic details is credited in any copy;
• A hyperlink and/or URL is included for the original metadata page; and
• The content is not changed in any way.
For more information, including our policy and submission procedure, please
contact the Repository Team at: E.mailbox@hud.ac.uk.
http://eprints.hud.ac.uk/
  
 
 
 
 
A VALIDATION OF THE 
OSWESTRY SPINAL 
RISK INDEX 
  
Abstract 
 
The purpose of this study was to validate the Oswestry Spinal Risk Index (OSRI) in 
an external population. The OSRI predicts survival in patients with metastatic spinal 
cord compression (MSCC). 
We analysed the data of 100 patients undergoing surgical intervention for MSCC at a 
tertiary spinal unit and recorded the primary tumour pathology and Karnofsky 
Performance Status to calculate the OSRI. Logistic regression models and survival 
plots were applied to the data in accordance with the original paper. Lower OSRI 
scores predicted longer survival. The OSRI score predicted survival accurately in 
74% of cases (p= 0.004). 
Our study has found that the OSRI is a significant predictor of survival at levels 
similar to those of the original authors and is a useful and simple tool in aiding 
complex decision making in patients presenting with MSCC.  
Keywords: spine; metastases; spinal cord compression; survival; prognosis. 
 
Introduction 
Metastatic cancer is one of the leading causes of death [1]. The skeletal system is 
the third most common site for metastases, and the spine is the most commonly 
affected part [1,2]. Ten year relative survival from cancer has increased from 
approximately 25% in the 1970s to 45% in 2007 across a range of cancers [3]. With 
significant improvements in survival for tumours with a predilection for spinal 
metastases (breast, prostate and renal cancer), the incidence of spinal metastasis is 
likely to increase. Approximately 20% of spinal metastasis cases exhibit neurological 
deficit due to spinal cord compression [4]. Untreated spinal metastasis results in the 
deterioration of life quality due to severe neurological deficits and intractable pain, 
which can shorten life expectancy with complications [5].  
 
The primary aims of surgery in the treatment of metastatic spinal cord compression 
are to preserve or recover neurological function, treat spinal instability and provide 
pain relief with the aim of maintaining functional independence and quality of life [6]. 
Advances in adjuvant treatments necessitate a multidisciplinary approach that 
optimizes the combination of surgery, radiation therapy and chemotherapy to 
maximise tumour control and minimise the morbidity of treatment. Although the role 
of surgery remains largely palliative, appropriate adjuvant therapy may provide 
excellent localized tumour control [7]. 
 
The appropriateness of surgery and the proposed intervention are selected on the 
basis of predicted prognosis. Scoring systems are used to try to predict survival that 
will in turn guide treatment decisions. A wide range of scoring systems have been 
introduced in recent years with the intention of predicting survival and therefore 
guiding treatment in patients with spinal metastases e.g. Tomita [8], Tokuhashi [9] 
and Bauer [10]. Prognosis is affected by the patient's general condition [8], the 
primary tumour type [8], the presence of extra spinal bony metastases [9], the 
number of metastases in the vertebral body [9], the severity of spinal cord palsy [9] 
and the presence of any major organ metastases [8-10]. 
 
The scoring systems differ greatly in the kind of parameters assessed and the 
weights assigned to these parameters in the determination of the total score [8-10]. 
As a result, for the same patient, it is possible that different survival periods might be 
calculated and contradictory treatment strategies advised [11]. The National Institute 
for Clinical Excellence (NICE) has produced guidelines for the treatment of patients 
with MSCC. These guidelines have been produced to aid overall patient 
management- from educating the patient on which symptoms to be concerned about 
through to recommendations for cancer network services [12]. The guidelines 
suggest that surgery should be carefully planned to maximise the probability of 
preserving spinal cord function without undue risk to the patient, taking into account 
their overall fitness and prognosis. [13] Whilst an accurate prognosis is desirable 
there is often time pressure for treatment to be undertaken which limits the time 
available for repeat staging investigations. The best neurological outcomes following 
surgery for MSCC are achieved if surgery is carried out within 48 hours [13]. 
The urgency for intervention twinned with the need for an accurate prognostication 
method has driven the development of scoring systems.  
 
The ideal scoring system can be applied to all patients, and be able to accurately and 
reproducibly predict survival in order to guide management. In recent years the 
revised Tokuhashi [9] and Tomita [8] scores have been widely used but validation 
studies have reported conflicting evidence in their ability to accurately predict survival 
[11,14]. Reliability may be increased in a sub-set of patients treated surgically [10, 
15]. 
 
The Oswestry Spinal Risk Index (OSRI) is a scoring system developed by Balain et 
al [16] that predicts survival in patients with MSCC. It is derived from the most 
predictive variables of the revised Tokuhashi [9], Tomita [8] and modified Bauer [10] 
scores. In a cohort of 199 patients with metastases, Balain et al  [16] found the most 
important factors in predicting survival were the primary tumour pathology (PTP) and 
general condition (GC) of the patient based upon the Karnofsky score [17]. The PTP 
and GC are allocated scores and the formula: PTP + 2-GC is used to calculate the 
OSRI score. The lower the OSRI score, the longer the predicted survival of the 
patient. 
The aim of this study was to carry out a validation of the OSRI. 
 
Methods 
Patients undergoing surgery for spinal metastases between January 2009 and 
November 2011 were identified from a prospectively recorded database at a tertiary 
referral centre for spinal surgery. The database records a detailed presenting history, 
past medical history, examination findings, investigation results and demographics. 
Electronic patient files were reviewed to identify those patients who had surgery for 
spinal metastases. Primary bone tumours of the spine and spinal cord tumours were 
excluded. 
 
Patients were analysed considering their survival status as at July 2013. The 
analysis was undertaken retrospectively. The primary tumour and general condition 
score was recorded for each patient, as well as the date of birth, date of surgery and 
date of death if applicable. The PTP score was allocated based on this speed of 
growth of the primary tumour, as used in the Tomita scoring system [8]. The OSRI 
was then calculated for each patient. The assessor was not blinded as to whether the 
patient was dead or alive at the time of analysis. 
A number of procedures were conducted to assess the validity of the OSRI score 
and its transferability across data sets; some of which are based on analyses 
presented by Balain et al [16]. Consistently with the analyses of Balain et al [16], and 
because of low numbers of patients in certain classes in the current analysis, 
patients classified with OSRI scores of 2 and 3, and patients classified with OSRI 
scores of 4 and 5 were combined into single classes. For all patients a Kaplan-Meier 
survival analysis was conducted to compare the survival experience of patients with 
varying OSRI scores. Median survival times and associated 95% confidence 
intervals were obtained for patients with each of the possible OSRI scores. Using the 
Mantel-Cox log rank statistic, pairwise comparisons of survival between patients in 
different groups were assessed. 
 
Nagelkerke's pseudo-R2 statistic was evaluated for a logistic regression analysis of 
patient survival using the OSRI score as a predictor and with patient age included in 
the model as a controlling variable. In this analysis the OSRI score was assumed to 
approximate to an interval-level variable, with mid-point coding given to combined 
groups. The Receiver Operating Characteristic (ROC) curve was also derived for the 
OSRI score and the area under the ROC curve calculated for the OSRI score 
variable to assess the capability of this index to distinguish between patients who 
survived to the end of the analysis period and those who died. An OSRI score 
corresponding to an optimal combination of sensitivity and specificity was also 
obtained.  
 
Linearity of the model was checked by creating categorical variables corresponding 
to all values of the OSRI score, and assessing the linear trend of parameter 
coefficients. Cross-validation of the existing data set was facilitated by partitioning 
the data set into a training data set of 80% of the original cohort; and a validation set 
of the remainder. A logistic regression analysis was conducted on the training data 
set. Regression parameters obtained from this analysis were applied to the validation 
set and the level of predictive capability assessed on the validation data set.  
 
Statistical significance in all inferential procedures was assumed to be indicated by p-
values of <0.05. 
 
Results 
Analysis was undertaken on one hundred patients undergoing spinal surgery for 
spinal metastases between January 2009 and November 2011, aged between 19 
and 88, with a mean age of 60.3 years (SD 12.4). The most common tumour type 
was breast (n=24) followed by lung (n=20). Seventy four patients died during the 
period of analysis; 26 survived until the end of analysis period and were hence 
recorded as censored observations. 
Median survival times and associated confidence intervals for the entire cohort and 
for the patient groups according to their OSRI score are summarized in Table 1. 
Table 1: Median survival times and confidence intervals for patients with 
differing OSRI scores 
OSRI score Median survival time 
(days) 
95% CI for survival time 
(days) 
1 (n=12) * * 
2/3 (n=56) 325 (140, 510) 
4/5 (n=11) 262 (170, 354) 
6 (n=11) 160 (55, 265) 
7(n=10) 58 (24, 92) 
All patients (n=100) 253 (165, 341) 
*Over 50% of patients survived in this group until the end of the analysis 
period 
Survival plots for each of the five OSRI classifications (Figure 1) shows distinct 
differences in survival experience, with greater survival being associated with lower 
OSRI scores. 
Figure 1: Survival curves for patients with varying OSRI scores 
 
 
Pairwise comparisons of survival between patients with OSRI score categories using 
the Mantel-Cox log rank statistic revealed substantive differences in survival 
experience between patients with OSRI scores 1 and 2/3. However survival 
experience between patients with other adjacent OSRI scores was not significantly 
different. Significant differences in survival experience between patients exhibiting 
greater modified OSRI score dissimilarity was observed; for example between 
patients with modified OSRI score 1 and patients with modified OSRI score of 4/5 or 
more; between patients with modified OSRI score 2/3 and patients with modified 
OSRI score of 6 or more; between patients with modified OSRI score 4/5 and 
OSRI=ͳ	OSRI=ʹ/͵	OSRI=Ͷ/ͷ	OSRI=͸	OSRI=͹	
patients with modified OSRI score of 7. All log-rank statistics and associated p-
values are summarized in Table 2. 
Table 2: Mantel-Cox log-rank statistics and p-values for comparison of survival 
experience of patients with differing OSRI scores 
OSRI score  
2/3 4/5 6 7 
1 2.82 (0.093) 7.07 (0.008) 7.12 (0.008) 8.07 (0.004) 
2/3 - 1.47 (0.225) 5.37 (0.020) 8.43 (0.004) 
4/5  - 1.67 (0.196) 4.17 (0.041) 
6   - 0.477 (0.490) 
Nagelkerke's pseudo-R2 statistic of 0.145 was obtained for a logistic regression 
analysis of patient survival using the OSRI score as a single predictor, rising to 0.167 
when patient ages were included as a controlling variable. The paper by Balain et al 
[16] proposing the OSRI found this score to have a Nagelkerke's pseudo R2 statistic 
of 0.28. The hazard ratio of 1.75 obtained for the OSRI score in both models 
indicates that the hazard of death is raised by 75% for each advance in the OSRI 
score. 
Model parameters from the logistic regression models are summarised in Table 3. It 
may be seen that while the OSRI score is a significant predictor of survival in both 
models, age is not a significant predictor in the controlled model. Examination of 
parameter coefficients in a model including all categories of the OSRI score as 
separate covariates verified the assumption of an approximate linear relationship 
between the OSRI score and the transformed outcome. 
 
 
 
 
 
 
 
Table 3: Logistic regression model parameters 
 Hazard 
ratio  
95% CI for hazard 
ratio 
p-value 
Univariate model (Nagelkerke’s 
R2=0.167) 
   
OSRI score 1.75 (1.19, 2.58) 0.004 
    
Controlled model (Nagelkerke’s 
R2=0.168) 
   
OSRI score 1.75  (1.19, 2.57) 0.005 
Age 1.01 (0.97, 1.05) 0.766 
 
Under the univariate model, 74 out of 100 patients (74%) were correctly classified: 
under the controlled model, 76 out of 100 patients were correctly classified (76%).  
The OSRI score was found to discriminate fairly well between patients who had died 
and those who had survived, with the area under the curve calculated to be 0.707. 
The ROC curve is illustrated in Figure 2. 
Figure 2: ROC curve for OSRI scores, showing diagonal reference line (area 
under reference line =0.500) 
 
 
 
Regression parameters derived from a logistic regression analysis of the training set 
applied to the validation set resulted in 14 out of 20 (70%) of cases being correctly 
predicted, a slight reduction from the value of 76% correctly predicted by applying the 
model to the full data set. The inclusion of age in the model did not affect predictive 
capability. 
 
Discussion 
 In our analysis of patients who had undergone surgery for spinal metastases we 
found that the OSRI was a substantive predictor of survival; showing similar levels of 
performance to those obtained by Balain et al [16]. The value under the ROC curve 
of the OSRI score of 0.707 represents fairly good ability of this measure to 
discriminate between patients who survive and those who do not, and also 
corresponds closely to the concordance value of 0.67 for the OSRI index obtained by 
Balain et al [16]. A distinct deterioration in survival experience with increasing OSRI 
score is exhibited, as also found by Balain et al [16]. 
 
Significant differences in survival experience may generally be observed between 
patients with adjacent OSRI scores two or more categories apart. However, survival 
experience between patients with adjacent OSRI scores is less clear. This contrasts 
with the findings of Balain et al [16], who noted significant differences in survival 
between most patient sub-groups; upon which the OSRI score was originally based. 
Non-significant differences in survival times between patients exhibiting OSRI score 
dissimilarity may well be due to the fact that our study was limited to 100 patients, 
with an unequal number of patients between OSRI groups. 
 
Our analysis showed that the hazard of deaths increased by 75% for each advance 
in the OSRI classification. This value is close to the corresponding value of a 91% 
increase obtained in the analysis of Balain et al [16]. In our series over 50% of the 
patients with an OSRI score of 1 were alive at the time of analysis. Those with an 
OSRI score of 7 had a median survival of just 58 days. Balain et al [16] found that 
patients with an OSRI score of 1 had a median survival of 23 months; those with a 
score of 7 had a median survival of just 1 month. This substantial difference is likely 
to prove useful in treatment making decisions for patients presenting with spinal 
metastases when surgical treatment is being considered. The OSRI is a user-friendly 
tool, as timely investigations to search for metastases; e.g. bone scans are not 
required to calculate the score. 
 
The cross-validation procedure undertaken on the data set in the current analysis 
provides further support for the reliability of the OSRI score, with an expected small 
reduction of 6 percentage points in the proportion of cases correctly classified on the 
validation set as compared to the full data set.  
 
Unlike the patients in the work of Balain et al [16], all patients in our study were 
treated surgically, therefore our survival figures relate to postoperative patients only. 
Due to the use of the electronic patient record system, no patient was lost to follow-
up, as dates of death were automatically entered on to the system. Hence censored 
data arises only from those patients remaining alive at the termination of the study. 
 
One weakness of the study is the limited number of patients that were analysed. A 
larger study would have greater power to detect differences in survival between 
patients with different OSRI scores. Another potential limitation is that only surgical 
patients were included. This was because our unit is a tertiary referral centre and the 
majority of patients with MSCC not having surgery will remain at their local hospital 
for treatment rather than being transferred. However, the exclusion of non-surgical 
patients improves the internal validity of the study and precludes confounding by 
surgical status. In an optimal model those patients having radiotherapy should also 
be included.  
 
Survival was defined from referral to our unit until date of death. An improvement 
could be made by determining the date of diagnosis of the primary tumour and 
calculating survival from then until death.  
From our experience we can confirm the OSRI is a significant predictor of survival 
and is a useful tool when considering surgical treatment for patients with spinal 
metastases. The OSRI has demonstrated good transferability across data sets, self-
consistency and predictive capability in a validated study. We recommend its use. 
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